Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences Inc (AKYA)
:AKYA
Holding AKYA?
Track your performance easily
AKYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.88 - $6.31
Previous CloseN/A
Volume11.73K
Average Volume (3M)1.05M
Market Cap
$136.82M
Enterprise Value$183.67M
Total Cash (Recent Filing)$21.66M
Total Debt (Recent Filing)$24.67M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Mar 10, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding49,572,746
10 Day Avg. Volume2,349,911
30 Day Avg. Volume1,045,640
Standard Deviation0.16
R-Squared0.12
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.61
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-3.80
Forecast
1Y Price Target
$3.63Price Target Upside28.72% Upside
Rating ConsensusHold
Number of Analyst Covering6
Akoya Biosciences News
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsAKYA's spatial biology capabilities in tissue combined with QTRX's ultra-sensitive detection tools for blood biomarkers create a stronger company.
Management And LeadershipAKYA's CEO, Brian McKelligon, plans to join the combined company, which is viewed positively given his expertise with AKYA's products and knowledge in oncology.
Strategic GrowthThe company is actively evaluating a range of strategic alternatives to identify the best path forward for sustainable growth, profitability, and long-term success.
Bears Say
Customer SpendingThe primary driver of the miss was lack of funding among Akoya's customer base, which has pressured sales of capital equipment in the life science tools sector.
EarningsThe company reported results that were meaningfully lower than estimates and consensus, primarily due to extended sales cycles and limited capital equipment funding.
Financial PerformanceAkoya has significantly lowered its 2024 revenue guidance and no longer believes it will achieve cash flow breakeven.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKYA FAQ
What was Akoya Biosciences Inc’s price range in the past 12 months?
Akoya Biosciences Inc lowest stock price was $1.88 and its highest was $6.31 in the past 12 months.
What is Akoya Biosciences Inc’s market cap?
Akoya Biosciences Inc’s market cap is $136.82M.
When is Akoya Biosciences Inc’s upcoming earnings report date?
Akoya Biosciences Inc’s upcoming earnings report date is Mar 10, 2025 which is in 47 days.
How were Akoya Biosciences Inc’s earnings last quarter?
Akoya Biosciences Inc released its earnings results on Nov 14, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.01.
Is Akoya Biosciences Inc overvalued?
According to Wall Street analysts Akoya Biosciences Inc’s price is currently Undervalued.
Does Akoya Biosciences Inc pay dividends?
Akoya Biosciences Inc does not currently pay dividends.
What is Akoya Biosciences Inc’s EPS estimate?
Akoya Biosciences Inc’s EPS estimate is -0.16.
How many shares outstanding does Akoya Biosciences Inc have?
Akoya Biosciences Inc has 49,572,746 shares outstanding.
What happened to Akoya Biosciences Inc’s price movement after its last earnings report?
Akoya Biosciences Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -23.003%.
Which hedge fund is a major shareholder of Akoya Biosciences Inc?
Currently, no hedge funds are holding shares in AKYA
---
Akoya Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.63 (28.72% Upside)
$3.63 (28.72% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 6.8%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.25%
12-Months-Change
Fundamentals
Return on Equity
-425.20%
Trailing 12-Months
Asset Growth
-26.67%
Trailing 12-Months
Company Description
Akoya Biosciences Inc
Akoya Biosciences (AKYA) is a biotechnology company based in the United States, specializing in the field of spatial biology. The company provides advanced solutions for the identification and analysis of biological markers in tissue samples. Its core products and services include the development and commercialization of cutting-edge imaging technologies and software designed to enhance the understanding of complex biological systems, particularly in the context of cancer research, immunology, and other therapeutic areas.
---
AKYA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Akoya Biosciences, with significant revenue declines and underperformance in instrument sales due to market constraints. However, improvements in operational efficiencies and strategic advancements in the clinical pipeline provide a positive outlook for long-term growth.Read More>---
AKYA Stock 12 Month Forecast
Average Price Target
$3.63
▲(28.72% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-25.75%
assigned a buy rating 2 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -25.75% per trade.
---